Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0046
Investigational
DT2216
Senolytic / BCL-xL degrader
Senescent-cell apoptosis with reduced platelet BCL-xL toxicity concept
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- PROTAC degrader
- Primary mechanism
- BCL-xL targeted degradation via VHL-recruiting PROTAC
- Primary market use
- Senolytic / oncology research
Pharmacology
- Molecular weight (Da)
- 1542.4
- Oral bioavailability
- Not established; large PROTAC
- Half-life
- ~1–12 h provisional PK estimate
- Route tags
- Route-dependent / verify
- Evidence level
- Preclinical/Clinical oncology
- Clinical status
- Investigational
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
PROTAC strategy may improve safety but remains high-cost research/oncology-grade